Pipeline

Our pipeline of antibody therapeutics includes in-house and partnered pre-clinical programs

GT-001 is a humanized IgG1 mAb with unrivaled fine-specificity, specifically targeting the tumor-associated Lewis Y (LeY, CD174) carbohydrate antigen without cross-reactivity to related carbohydrates expressed on blood cells. GT-001 binds to a high percentage of breast cancers non-small cell lung cancer, colorectal cancer, head and neck cancer, small cell lung cancer and ovarian cancer patient samples and is effectively internalized, making it suitable for ADC or CAR development.

GT-002 is an IgG1 mAb targeting LYPD3 (C4.4A) with increased tumor-specificity. LYPD3 is expressed in various cancer indications with high medical need, including squamous cell carcinoma of the head and neck (HNSCC). Upon binding to LYPD3, the antibody is effectively internalized. The improved tumor-specificity of GT-002 results in reduced binding to healthy-tissue expressed LYPD3 making it suitable for the development of highly potent therapies like ADCs or CARs.

GT-00A is a humanized IgG1 mAb targeting tumor-associated (TA)-MUC1. GT-00A is in pre-clinical development as an IL-15-based immuno-cytokine and as ADC. TA-MUC1 is a novel tumor-specific protein/carbohydrate combined glyco-epitope on the tumor-marker MUC1. The target is expressed on many epithelial tumor types including primary tumor, metastases and cancer stem cells, but is virtually absent on normal cells. Main target indications are ovarian, lung, breast, further potential for treatment of cervical, endometrial, gastrointestinal, kidney, urothelial and other cancers.

GT-00A based IL-15 immuno-cytokine: Cytokines have long been used for cancer therapy to activate the immune system, but side effects and short half-life limit their therapeutic application. The concept of tumor-specific targeting to the tumor micro environment to use the full potential of IL-15 biology is unique within the competitive field of IL-15 (super)agonists. Our immune-cytokine attracts and activates immune cells (e.g. T and NK cells) directly at the tumor site thereby turning an “immune desert” into a “hot” tumor and inducing tumor cell lysis. A comprehensive non-clinical data package is available and the First in Human study is planned. We are now actively looking for a partner for co-development/out-licensing.